<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="5a3dbd4a-e02f-4ca5-b23f-9e5c62585e9d"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use <content styleCode="bold">MERCAPTOPURINE TABLETS</content> safely and effectively.  See full prescribing information for <content styleCode="bold">MERCAPTOPURINE TABLETS</content>.<br/>Â <br/>
      <content styleCode="bold">MERCAPTOPURINE tablets, for oral use</content>
      <br/>Initial U.S. Approval: 1953</title>
   <effectiveTime value="20250221"/>
   <setId root="15904472-4c32-4224-95d3-eb131a7ff9c8"/>
   <versionNumber value="17"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="059295980" root="1.3.6.1.4.1.519.1"/>
            <name>Mylan Pharmaceuticals Inc.</name>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="cfab7318-b4ae-4e5d-9fe6-0182206383cf"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250221"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0378-3547" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Mercaptopurine</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>mercaptopurine</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="50"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="E7WED276I5" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MERCAPTOPURINE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="PKK6MUZ20G" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MERCAPTOPURINE ANHYDROUS</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STARCH, CORN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="368GB5141J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM LAURYL SULFATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="25"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0378-3547-52" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20050701"/>
                                    <high value="20260531"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="250"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0378-3547-25" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20050701"/>
                                    <high value="20250630"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA040594" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="completed"/>
                           <effectiveTime>
                              <low value="20050701"/>
                              <high value="20260531"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE">
                              <originalText>off-white to light yellow</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="10" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="2" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">M;547</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID_ADB39073-3299-4A3A-B5DA-1B7553BE8982">
               <id root="b53ee461-1bee-45e9-8840-5fd0fc88b7da"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20241128"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph/>
                        <paragraph>Warnings and Precautions, Hepatotoxicity (<linkHtml href="#ID_bfef2dcf-ce51-481d-9c8e-ed6f0da20250">5.2</linkHtml>)Â Â Â Â Â 7/2024</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_D332DE77-BA06-43D5-962E-FD4CDAAC0F0D">
               <id root="6b5db115-acc0-4028-8de4-1490e25ce355"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE </title>
               <effectiveTime value="20241128"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Mercaptopurine tablets are a nucleoside metabolic inhibitor indicated for treatment of adult and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen. (<linkHtml href="#ID_24f2346a-38b4-40d6-8b06-3a62653a86f1">1.1</linkHtml>) </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_24f2346a-38b4-40d6-8b06-3a62653a86f1">
                     <id root="4a9f82b2-b9f4-4c3e-9a05-e77e4c999836"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.1 Acute Lymphoblastic Leukemia </title>
                     <text>
                        <paragraph>Mercaptopurine tablets are indicated for treatment of adult and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen. </paragraph>
                     </text>
                     <effectiveTime value="20241128"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_CA7761F0-1B72-4F2E-A89D-E2376DAA3185">
               <id root="2d647f5d-5a7d-450a-bdee-d9e293a7adf1"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION </title>
               <effectiveTime value="20250221"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>â¢</caption>The recommended starting dose of mercaptopurine tablets is 1.5 mg/kg to 2.5 mg/kg orally once daily as part of a combination chemotherapy maintenance regimen. Adjust dose to maintain desirable absolute neutrophil count and for excessive myelosuppression. (<linkHtml href="#ID_6cd83867-14b0-448f-a1ab-ab96b6b8df41">2.1</linkHtml>) </item>
                           <item>
                              <caption>â¢</caption>
                              <content styleCode="underline">Renal Impairment</content>: Use the lowest recommended starting dose or increase the dosing interval. (<linkHtml href="#ID_685380f0-baaa-4459-b776-9e3187f924e0">2.3</linkHtml>, <linkHtml href="#ID_2baab33d-4d76-43e2-85c6-85e5ef0bfc50">8.6</linkHtml>) </item>
                           <item>
                              <caption>â¢</caption>
                              <content styleCode="underline">Hepatic Impairment</content>: Use the lowest recommended starting dose. (<linkHtml href="#ID_685380f0-baaa-4459-b776-9e3187f924e0">2.3</linkHtml>, <linkHtml href="#ID_b4c97d6f-12ca-4cd5-b9a5-26a7c4fb9df2">8.7</linkHtml>) </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_6cd83867-14b0-448f-a1ab-ab96b6b8df41">
                     <id root="68f87396-f83a-4c63-b7ef-3bef8eebdc08"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Recommended Dosage  </title>
                     <text>
                        <paragraph>The recommended starting dosage of mercaptopurine tablets is 1.5 mg/kg to 2.5 mg/kg orally once daily as part of combination chemotherapy maintenance regimen. A recommended dosage for patients less than 17 kg is not achievable, because the only available strength is 50 mg. Take mercaptopurine tablets either consistently with or without food.</paragraph>
                        <paragraph>After initiating mercaptopurine tablets, monitor complete blood count (CBC) and adjust the dose to maintain absolute neutrophil count (ANC) at a desirable level and for excessive myelosuppression. Evaluate the bone marrow in patients with prolonged myelosuppression or repeated episodes of myelosuppression to assess leukemia status and marrow cellularity. </paragraph>
                        <paragraph>Evaluate thiopurine S-methyltransferase (TPMT) and nucleotide diphosphatase (NUDT15) status in patients with severe myelosuppression or repeated episodes or myelosuppression <content styleCode="italics">[see <linkHtml href="#ID_0e3b37a1-bd9b-4476-9745-464f5b13b677">Dosage and Administration (2.2)</linkHtml>]</content>. </paragraph>
                        <paragraph>Do not administer to patients who are unable to swallow tablets.</paragraph>
                        <paragraph>If a patient misses a dose, instruct the patient to continue with the next scheduled dose. </paragraph>
                        <paragraph>Mercaptopurine tablets are a cytotoxic drug. Follow special handling and disposal procedures.</paragraph>
                     </text>
                     <effectiveTime value="20250221"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_0e3b37a1-bd9b-4476-9745-464f5b13b677">
                     <id root="8579193d-9a00-441e-b373-c95c474b94b2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Dosage Modifications in Patients with TPMT and NUDT15 Deficiency  </title>
                     <text>
                        <paragraph>Consider testing for TPMT and NUDT15 deficiency in patients who experience severe myelosuppression or repeated episodes of myelosuppression <content styleCode="italics">[see <linkHtml href="#ID_5b7ca743-e272-49eb-b06f-d8aa29349acc">Warnings and Precautions (5.1)</linkHtml>, <linkHtml href="#ID_531b98a2-c74a-4a80-8fde-0094c2cfef7e">Clinical Pharmacology (12.5)</linkHtml>]</content>. </paragraph>
                     </text>
                     <effectiveTime value="20241128"/>
                     <component>
                        <section ID="ID_5cce560a-cb94-420c-a777-760e9f6c1d30">
                           <id root="3191951d-2745-4820-8be0-36d0e2789206"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Homozygous Deficiency in either TPMT or NUDT15</content>
                              <content styleCode="bold">
                                 <content styleCode="italics"/>
                              </content>
                           </title>
                           <text>
                              <paragraph>Patients with homozygous deficiency of either enzyme typically require 10% or less of the recommended dosage. Reduce the recommended starting dosage of mercaptopurine tablets in patients who are known to have homozygous TPMT or NUDT15 deficiency. </paragraph>
                           </text>
                           <effectiveTime value="20241128"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_b17f1f7b-d7ec-4d69-8aac-c65a1015b6e3">
                           <id root="495264d9-dde4-4af3-b714-39ef465f42f7"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Heterozygous Deficiency in TPMT and/or NUDT15</content>
                              <content styleCode="bold">
                                 <content styleCode="italics"/>
                              </content>
                           </title>
                           <text>
                              <paragraph>Reduce the mercaptopurine tablets dose based on tolerability. Most patients with heterozygous TPMT or NUDT15 deficiency tolerate the recommended dosage, but some require a dose reduction based on adverse reactions. Patients who are heterozygous for both TPMT and NUDT15 may require more substantial dose reductions.</paragraph>
                           </text>
                           <effectiveTime value="20241128"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_685380f0-baaa-4459-b776-9e3187f924e0">
                     <id root="25d0a0aa-d2f0-496e-b5be-244ad8809fb3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Dosage Modifications in Renal and Hepatic Impairment  </title>
                     <effectiveTime value="20241128"/>
                     <component>
                        <section ID="ID_3aa0b758-d862-4f38-8135-97087c2ca3ed">
                           <id root="c4e6e529-b93d-4229-b419-c4add778cfe1"/>
                           <code code="88828-9" codeSystem="2.16.840.1.113883.6.1" displayName="RENAL IMPAIRMENT SUBSECTION"/>
                           <title>
                              <content styleCode="underline">Renal Impairment</content>
                              <content styleCode="bold">
                                 <content styleCode="italics"/>
                              </content>
                           </title>
                           <text>
                              <paragraph>Use the lowest recommended starting dosage for mercaptopurine tablets in patients with renal impairment (CLcr less than 50 mL/min). Adjust the dosage to maintain absolute neutrophil count (ANC) at a desirable level and for adverse reactions <content styleCode="italics">[see <linkHtml href="#ID_2baab33d-4d76-43e2-85c6-85e5ef0bfc50">Uses in Specific Populations (8.6)</linkHtml>]</content>. </paragraph>
                           </text>
                           <effectiveTime value="20241128"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_e35d424c-e896-4eb1-9bae-798a928a96d7">
                           <id root="46f6c9ce-690e-4ee9-b7a2-8f968c4af950"/>
                           <code code="88829-7" codeSystem="2.16.840.1.113883.6.1" displayName="HEPATIC IMPAIRMENT SUBSECTION"/>
                           <title>
                              <content styleCode="underline">Hepatic Impairment</content>
                              <content styleCode="bold">
                                 <content styleCode="italics"/>
                              </content>
                           </title>
                           <text>
                              <paragraph>Use the lowest recommended starting dosage for mercaptopurine tablets in patients with hepatic impairment. Adjust the dosage to maintain absolute neutrophil count (ANC) at a desirable level and for adverse reactions <content styleCode="italics">[see <linkHtml href="#ID_b4c97d6f-12ca-4cd5-b9a5-26a7c4fb9df2">Uses in Specific Populations (8.7)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20241128"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_7729bf9d-d50f-4c5f-a3f7-8f1f99e8bc63">
                     <id root="49d14927-a1ef-472c-940e-9fab6dc1712f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Dosage Modification with Concomitant Use of Allopurinol  </title>
                     <text>
                        <paragraph>Reduce the dose of mercaptopurine tablets to one-third to one-quarter of the current dosage when coadministered with allopurinol <content styleCode="italics">[see <linkHtml href="#ID_0ee61f0e-9ed1-4817-9ae2-2a16f9fa4c0b">Drug Interactions (7.1)</linkHtml>]</content>. </paragraph>
                     </text>
                     <effectiveTime value="20241128"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_3197E083-76DD-48B8-949F-F5D475162469">
               <id root="d5f7c6de-3e22-4ed8-aab3-faac8daf942a"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS </title>
               <text>
                  <paragraph>Mercaptopurine Tablets, USP are available containing 50 mg of mercaptopurine, USP. </paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>â¢</caption>The 50 mg tablets are off-white to light yellow, round, scored tablets debossed with <content styleCode="bold">M</content> above the score and <content styleCode="bold">547</content> below the score on one side of the tablet and blank on the other side.</item>
                  </list>
               </text>
               <effectiveTime value="20220311"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Tablets: 50 mg (<linkHtml href="#ID_3197E083-76DD-48B8-949F-F5D475162469">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_EE2C2F5F-6C29-45B4-A191-78030EC75124">
               <id root="2d2431a1-c009-43a1-a8ba-a56d8c3039bb"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS </title>
               <text>
                  <paragraph>None.</paragraph>
               </text>
               <effectiveTime value="20241128"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>None. </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_37246AA0-AEF1-4F50-8858-8042A72BA0BA">
               <id root="2510905c-d62c-405f-988d-89e7cf0fb1cc"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS </title>
               <effectiveTime value="20250221"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>â¢</caption>
                              <content styleCode="underline">Myelosuppression</content>: Monitor complete blood count (CBC) and adjust the dose of mercaptopurine tablets for excessive myelosuppression. Consider testing in patients with severe myelosuppression or repeated episodes of myelosuppression for thiopurine S-methyltransferase (TPMT) or nucleotide diphosphatase (NUDT15) deficiency. Patients with homozygous or homozygous TPMT or NUDT15 deficiency may require a dose reduction. (<linkHtml href="#ID_0e3b37a1-bd9b-4476-9745-464f5b13b677">2.2</linkHtml>, <linkHtml href="#ID_5b7ca743-e272-49eb-b06f-d8aa29349acc">5.1</linkHtml>)</item>
                           <item>
                              <caption>â¢</caption>
                              <content styleCode="underline">Hepatotoxicity</content>: Monitor transaminases, alkaline phosphatase and bilirubin. Withhold mercaptopurine tablets at onset of hepatotoxicity. (<linkHtml href="#ID_bfef2dcf-ce51-481d-9c8e-ed6f0da20250">5.2</linkHtml>) </item>
                           <item>
                              <caption>â¢</caption>
                              <content styleCode="underline">Immunosuppression</content>: Response to all vaccines may be diminished and there is a risk of infection with live virus vaccines. Consult immunization guidelines for immunocompromised patients. (<linkHtml href="#ID_ebb44fcf-c297-4999-85cb-09f0b5a6528a">5.3</linkHtml>) </item>
                           <item>
                              <caption>â¢</caption>
                              <content styleCode="underline">Treatment Related Malignancies</content>: Aggressive and fatal cases of hepatosplenic T-cell lymphoma have occurred. (<linkHtml href="#ID_0d57b796-f3e7-4c3f-85e5-d25f7a7a2aa3">5.4</linkHtml>) </item>
                           <item>
                              <caption>â¢</caption>
                              <content styleCode="underline">Macrophage Activation Syndrome</content>: Monitor for and treat promptly; discontinue mercaptopurine tablets. (<linkHtml href="#ID_d5244788-7a3e-4341-884c-47fe7ba3c852">5.5</linkHtml>) </item>
                           <item>
                              <caption>â¢</caption>
                              <content styleCode="underline">Embryo-Fetal Toxicity</content>: Can cause fetal harm. Advise patients of reproductive potential of the potential risk to a fetus and to use effective contraception. (<linkHtml href="#ID_bd8104ed-c6a2-41ae-bf66-8f98042f266b">5.6</linkHtml>, <linkHtml href="#ID_29D21046-6E89-4235-96D8-0AFB48D9C7F6">8.1</linkHtml>, <linkHtml href="#ID_60726749-C0D9-42D8-A284-C24558949441">8.3</linkHtml>) </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_5b7ca743-e272-49eb-b06f-d8aa29349acc">
                     <id root="da9469f9-6802-4a5f-8cf2-0ea5961005ef"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Myelosuppression  </title>
                     <text>
                        <paragraph>The most consistent, dose-related adverse reaction is myelosuppression, manifested by anemia, leukopenia, thrombocytopenia, or any combination of these. Monitor CBC and adjust the dosage of mercaptopurine tablets for excessive myelosuppression <content styleCode="italics">[see <linkHtml href="#ID_6cd83867-14b0-448f-a1ab-ab96b6b8df41">Dosage and Administration (2.1)</linkHtml>]</content>. </paragraph>
                        <paragraph>Consider testing for TPMT or NUDT15 deficiency in patients with severe myelosuppression or repeated episodes of myelosuppression. TPMT genotyping or phenotyping (red blood cell TPMT activity) and NUDT15 genotyping can identify patients who have reduced activity of these enzymes. Patients with heterozygous or homozygous TPMT or NUDT15 deficiency may require a dose reduction <content styleCode="italics">[see <linkHtml href="#ID_0e3b37a1-bd9b-4476-9745-464f5b13b677">Dosage and Administration (2.2),</linkHtml>Â <linkHtml href="#ID_531b98a2-c74a-4a80-8fde-0094c2cfef7e">Clinical Pharmacology (12.5)</linkHtml>]</content>. </paragraph>
                        <paragraph>Myelosuppression can be exacerbated by coadministration with allopurinol, aminosalicylates or other products that cause myelosuppression <content styleCode="italics">[see <linkHtml href="#ID_0ee61f0e-9ed1-4817-9ae2-2a16f9fa4c0b">Drug Interactions (7.1</linkHtml>, <linkHtml href="#ID_5ed1c58a-4de7-49a9-9f9a-6a456652a87b">7.3</linkHtml>, <linkHtml href="#ID_7bec32a5-b81b-414c-b540-4c3cb03bfdbe">7.4)</linkHtml>]</content>. Reduce the dose of mercaptopurine tablets when coadministered with allopurinol <content styleCode="italics">[see <linkHtml href="#ID_7729bf9d-d50f-4c5f-a3f7-8f1f99e8bc63">Dosage and Administration (2.4)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241128"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_bfef2dcf-ce51-481d-9c8e-ed6f0da20250">
                     <id root="110ce0af-9bb9-44c9-80ff-30744d07889c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Hepatotoxicity  </title>
                     <text>
                        <paragraph>Mercaptopurine is hepatotoxic. There are reports of deaths attributed to hepatic necrosis associated with the administration of mercaptopurine. Hepatic injury can occur with any dosage but seems to occur with greater frequency when the recommended dosage is exceeded. In some patients, jaundice has cleared following withdrawal of mercaptopurine and reappeared with rechallenge. </paragraph>
                        <paragraph>Usually, clinically detectable jaundice appears early in the course of treatment (1 to 2 months); however, jaundice has been reported as early as 1 week and as late as 8 years after the starting mercaptopurine. The hepatotoxicity has been associated in some cases with anorexia, diarrhea, <content styleCode="xmChange">jaundice, ascites, and pruritus</content>. Hepatic encephalopathy has occurred. </paragraph>
                        <paragraph>Monitor serum transaminase levels, alkaline phosphatase, and bilirubin levels at weekly intervals when first beginning therapy and at monthly intervals thereafter. Monitor liver tests more frequently in patients who are receiving mercaptopurine tablets with other hepatotoxic products <content styleCode="italics">[see <linkHtml href="#ID_2d701531-f66e-4dff-b6ae-75550c1479d7">Drug Interactions (7.5)</linkHtml>] </content>or with known pre-existing liver disease. Withhold mercaptopurine tablets at onset of hepatotoxicity.</paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Intrahepatic Cholestasis of Pregnancy</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Postmarketing cases of intrahepatic cholestasis of pregnancy (ICP) have been reported in patients with inflammatory bowel disease who received mercaptopurine during pregnancy. Mercaptopurine tablets are not indicated for use in inflammatory bowel disease <content styleCode="italics">[see <linkHtml href="#ID_24f2346a-38b4-40d6-8b06-3a62653a86f1">Indications and Usage (1.1)</linkHtml>]</content>.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Discontinue mercaptopurine tablets if ICP develops in a pregnant woman.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250221"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_ebb44fcf-c297-4999-85cb-09f0b5a6528a">
                     <id root="cc03b163-ea2a-4159-aa6b-f0fa8c224d75"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Immunosuppression  </title>
                     <text>
                        <paragraph>Mercaptopurine is immunosuppressive and may impair the immune response to infectious agents or vaccines. Due to the immunosuppression associated with maintenance chemotherapy for ALL, response to all vaccines may be diminished and there is a risk of infection with live virus vaccines. Consult immunization guidelines for immunocompromised patients.</paragraph>
                     </text>
                     <effectiveTime value="20241128"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_0d57b796-f3e7-4c3f-85e5-d25f7a7a2aa3">
                     <id root="8f91b236-6fa2-4b18-a1f2-ffe4fef002ef"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Treatment Related Malignancies  </title>
                     <text>
                        <paragraph>Hepatosplenic T-cell lymphoma has been reported in patients treated with mercaptopurine for inflammatory bowel disease (IBD), an unapproved use. Mercaptopurine is mutagenic in animals and humans, carcinogenic in animals, and may increase the risk of secondary malignancies.</paragraph>
                        <paragraph>Patients receiving immunosuppressive therapy, including mercaptopurine, are at an increased risk of developing lymphoproliferative disorders and other malignancies, notably skin cancers (melanoma and non-melanoma), sarcomas (Kaposi's and non-Kaposi's) and uterine cervical cancer in situ. The increased risk appears to be related to the degree and duration of immunosuppression. It has been reported that discontinuation of immunosuppression may provide partial regression of the lymphoproliferative disorder. </paragraph>
                        <paragraph>A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. A combination of multiple immunosuppressants, given concomitantly increases the risk of Epstein-Barr virus (EBV)-associated lymphoproliferative disorders.</paragraph>
                     </text>
                     <effectiveTime value="20241128"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_d5244788-7a3e-4341-884c-47fe7ba3c852">
                     <id root="aa10736e-1fdf-4999-a4f4-bf1eb0798efb"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Macrophage Activation Syndrome  </title>
                     <text>
                        <paragraph>Macrophage activation syndrome (MAS) (hemophagocytic lymphohistiocytosis) is a known, life-threatening disorder that may develop in patients with autoimmune conditions, in particular with inflammatory bowel disease (IBD), and there could potentially be an increased susceptibility for developing the condition with the use of mercaptopurine (an unapproved use). If MAS occurs, or is suspected, discontinue mercaptopurine tablets. Monitor for and promptly treat infections such as EBV and cytomegalovirus (CMV), as these are known triggers for MAS. </paragraph>
                     </text>
                     <effectiveTime value="20241128"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_bd8104ed-c6a2-41ae-bf66-8f98042f266b">
                     <id root="91309f1f-6a1c-4fab-9fef-c8d6f55a0841"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Embryo-Fetal Toxicity  </title>
                     <text>
                        <paragraph>Mercaptopurine tablets can cause fetal harm when administered to a pregnant woman. An increased incidence of miscarriage has been reported in women who received mercaptopurine in the first trimester of pregnancy. Adverse embryo-fetal findings, including miscarriage and stillbirth, have been reported in women who received mercaptopurine after the first trimester of pregnancy. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with mercaptopurine tablets and for 6 months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with mercaptopurine tablets and for 3 months after the last dose <content styleCode="italics">[see <linkHtml href="#ID_29D21046-6E89-4235-96D8-0AFB48D9C7F6">Use in Specific Populations (8.1</linkHtml>, <linkHtml href="#ID_60726749-C0D9-42D8-A284-C24558949441">8.3)</linkHtml>]</content>. </paragraph>
                     </text>
                     <effectiveTime value="20241128"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_74C5163C-3355-4E2D-91FA-C60F2ACE8531">
               <id root="e73c8e5f-d62b-4492-9d7e-2cb7113b52e5"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS </title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are described elsewhere in the labeling: </paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>â¢</caption>Myelosuppression <content styleCode="italics">[see <linkHtml href="#ID_5b7ca743-e272-49eb-b06f-d8aa29349acc">Warnings and Precautions (5.1)</linkHtml>] </content>
                     </item>
                     <item>
                        <caption>â¢</caption>Hepatotoxicity <content styleCode="italics">[see <linkHtml href="#ID_bfef2dcf-ce51-481d-9c8e-ed6f0da20250">Warnings and Precautions (5.2)</linkHtml>] </content>
                     </item>
                     <item>
                        <caption>â¢</caption>Immunosuppression <content styleCode="italics">[see <linkHtml href="#ID_ebb44fcf-c297-4999-85cb-09f0b5a6528a">Warnings and Precautions (5.3)</linkHtml>] </content>
                     </item>
                     <item>
                        <caption>â¢</caption>Treatment related malignancies <content styleCode="italics">[see <linkHtml href="#ID_0d57b796-f3e7-4c3f-85e5-d25f7a7a2aa3">Warnings and Precautions (5.4)</linkHtml>] </content>
                     </item>
                     <item>
                        <caption>â¢</caption>Macrophage activation syndrome <content styleCode="italics">[see <linkHtml href="#ID_d5244788-7a3e-4341-884c-47fe7ba3c852">Warnings and Precautions (5.5)</linkHtml>] </content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20241128"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reaction (&gt; 20%) is myelosuppression, including anemia, leukopenia and thrombocytopenia. Adverse reactions occurring in 5% to 20% of patients include anorexia, nausea, vomiting, diarrhea, malaise and rash. (<linkHtml href="#ID_00f84b8b-1f8f-4650-9099-8e1c121f67d3">6.1</linkHtml>) </paragraph>
                        <paragraph>Â </paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact </content>
                           <content styleCode="bold">Mylan at 1-877-446-3679 (1-877-4-INFO-RX)</content>
                           <content styleCode="bold"> or FDA at 1-800-FDA-1088 or <linkHtml href="http://www.fda.gov/medwatch">www.fda.gov/medwatch.</linkHtml>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_00f84b8b-1f8f-4650-9099-8e1c121f67d3">
                     <id root="9998f634-8a96-49a6-8660-34bb74349745"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Trials Experience  </title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. </paragraph>
                        <paragraph>Based on multicenter cooperative group ALL trials, the most common adverse reaction occurring in &gt; 20% of patients was myelosuppression, including anemia, neutropenia, lymphopenia and thrombocytopenia. Adverse reactions occurring in 5% to 20% of patients included anorexia, nausea, vomiting, diarrhea, malaise and rash. Adverse reactions occurring in &lt; 5 % of patients included urticaria, hyperuricemia, oral lesions, increased transaminases, hyperbilirubinemia, hyperpigmentation, infections, and pancreatitis. Oral lesions resemble thrush rather than antifolic ulcerations. Delayed or late adverse reactions include hepatic fibrosis, hyperbilirubinemia, alopecia, pulmonary fibrosis, oligospermia and secondary malignancies <content styleCode="italics">[see <linkHtml href="#ID_5b7ca743-e272-49eb-b06f-d8aa29349acc">Warnings and Precautions (5.1</linkHtml>, <linkHtml href="#ID_bfef2dcf-ce51-481d-9c8e-ed6f0da20250">5.2)</linkHtml>]</content>. </paragraph>
                        <paragraph>Drug fever has been reported with mercaptopurine. </paragraph>
                        <paragraph>Additional adverse reactions that have been reported in patients who have received mercaptopurine include photosensitivity, hypoglycemia, and portal hypertension. </paragraph>
                     </text>
                     <effectiveTime value="20241128"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_c0c43020-ba4b-47d4-b0a0-b414c4fc111b">
                     <id root="197b5b04-7be1-4e63-a3a5-7dc0ea1b9efa"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Postmarketing Experience </title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during postapproval use of mercaptopurine tablets. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These reactions include: intrahepatic cholestasis of pregnancy (ICP).</paragraph>
                     </text>
                     <effectiveTime value="20241128"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_239D3E7F-1B20-4ED4-BEE2-BEA747C1EBC5">
               <id root="43b769f3-4ada-44e3-91d4-b7c41db67b62"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS </title>
               <effectiveTime value="20241128"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>â¢</caption>
                              <content styleCode="underline">Allopurinol</content>:Â Reduce the dose of mercaptopurine tablets when co-administered with allopurinol. (<linkHtml href="#ID_7729bf9d-d50f-4c5f-a3f7-8f1f99e8bc63">2.4</linkHtml>, <linkHtml href="#ID_0ee61f0e-9ed1-4817-9ae2-2a16f9fa4c0b">7.1</linkHtml>) </item>
                           <item>
                              <caption>â¢</caption>
                              <content styleCode="underline">Warfarin</content>: Mercaptopurine tablets may decrease the anticoagulant effect. (<linkHtml href="#ID_7641fac2-289b-4ae5-bafc-ff277064370e">7.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_0ee61f0e-9ed1-4817-9ae2-2a16f9fa4c0b">
                     <id root="ce3e344b-8cdc-425c-9bd4-728105630997"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Allopurinol  </title>
                     <text>
                        <paragraph>Allopurinol can inhibit the first-pass oxidative metabolism of mercaptopurine by xanthine oxidase, which can lead to an increased risk of mercaptopurine adverse reactions (i.e., myelosuppression, nausea, and vomiting) <content styleCode="italics">[see <linkHtml href="#ID_5b7ca743-e272-49eb-b06f-d8aa29349acc">Warnings and Precautions (5.1)</linkHtml>, <linkHtml href="#ID_00f84b8b-1f8f-4650-9099-8e1c121f67d3">Adverse Reactions (6.1)</linkHtml>]</content>. Reduce the dose of mercaptopurine tablets when coadministered with allopurinol <content styleCode="italics">[see <linkHtml href="#ID_7729bf9d-d50f-4c5f-a3f7-8f1f99e8bc63">Dosage and Administration (2.4)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241128"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_7641fac2-289b-4ae5-bafc-ff277064370e">
                     <id root="28463515-f4e9-476a-a041-f6b84eb7a5b1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2 Warfarin  </title>
                     <text>
                        <paragraph>The concomitant administration of mercaptopurine tablets and warfarin may decrease the anticoagulant effectiveness of warfarin. Monitor the international normalized ratio (INR) in patients receiving warfarin and adjust the warfarin dosage as appropriate. </paragraph>
                     </text>
                     <effectiveTime value="20241128"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_5ed1c58a-4de7-49a9-9f9a-6a456652a87b">
                     <id root="78e321b1-5b6c-4690-a63b-cdb540f74835"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.3 Myelosuppressive Products  </title>
                     <text>
                        <paragraph>Mercaptopurine tablets can cause myelosuppression. Myelosuppression may be increased when mercaptopurine tablets are coadministered with other products that cause myelosuppression. Enhanced myelosuppression has been noted in some patients also receiving trimethoprim-sulfamethoxazole. Monitor the CBC and adjust the dose of mercaptopurine tablets for excessive myelosuppression <content styleCode="italics">[see <linkHtml href="#ID_6cd83867-14b0-448f-a1ab-ab96b6b8df41">Dosage and Administration (2.1)</linkHtml>, <linkHtml href="#ID_5b7ca743-e272-49eb-b06f-d8aa29349acc">Warnings and Precautions (5.1)</linkHtml>]</content>. </paragraph>
                     </text>
                     <effectiveTime value="20241128"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_7bec32a5-b81b-414c-b540-4c3cb03bfdbe">
                     <id root="99b0b2f4-a28d-4626-a9cd-6449a29fc409"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.4 Aminosalicylates  </title>
                     <text>
                        <paragraph>Aminosalicylates (e.g., mesalamine, olsalazine or sulfasalazine) may inhibit the TPMT enzyme, which may increase the risk of myelosuppression when coadministered with mercaptopurine tablets. When aminosalicylates and mercaptopurine tablets are coadministered, use the lowest possible doses for each drug and monitor more frequently for myelosuppression <content styleCode="italics">[see <linkHtml href="#ID_5b7ca743-e272-49eb-b06f-d8aa29349acc">Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241128"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_2d701531-f66e-4dff-b6ae-75550c1479d7">
                     <id root="beeea9f2-f510-4f49-91e1-98ceff623e8c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.5 Hepatotoxic Products  </title>
                     <text>
                        <paragraph>Mercaptopurine tablets can cause hepatotoxicity. Hepatotoxicity may be increased when mercaptopurine tablets are coadministered with other products that cause hepatotoxicity. Monitor liver tests more frequently in patients who are receiving mercaptopurine tablets with other hepatotoxic products <content styleCode="italics">[see <linkHtml href="#ID_bfef2dcf-ce51-481d-9c8e-ed6f0da20250">Warnings and Precautions (5.2)</linkHtml>]</content>. </paragraph>
                     </text>
                     <effectiveTime value="20241128"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_DF93A72A-42F8-4375-B8F3-C90714A7F7BC">
               <id root="44a140ae-2000-4e1e-a851-2178568bf5b6"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS </title>
               <effectiveTime value="20241128"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>â¢</caption>
                              <content styleCode="underline">Lactation</content>: Advise not to breastfeed. (<linkHtml href="#ID_C62D3003-4FC5-4056-81CB-BF17600F0F9F">8.2</linkHtml>) </item>
                           <item>
                              <caption>â¢</caption>
                              <content styleCode="underline">Infertility</content>: Can impair fertility. (<linkHtml href="#ID_60726749-C0D9-42D8-A284-C24558949441">8.3</linkHtml>) </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_29D21046-6E89-4235-96D8-0AFB48D9C7F6">
                     <id root="fb5a2d8e-1633-4b21-8301-14c834d84a83"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy </title>
                     <effectiveTime value="20241128"/>
                     <component>
                        <section ID="ID_2c866d7d-8533-4e11-97b0-6c60a4836c43">
                           <id root="bbcf80df-a54d-4bdb-81cf-083f45cddad9"/>
                           <code code="69759-9" codeSystem="2.16.840.1.113883.6.1" displayName="RISKS"/>
                           <title>
                              <content styleCode="underline">Risk Summary</content>
                              <content styleCode="bold">
                                 <content styleCode="italics"/>
                              </content>
                           </title>
                           <text>
                              <paragraph>Mercaptopurine tablets can cause fetal harm when administered to a pregnant woman <content styleCode="italics">[see <linkHtml href="#ID_E44834E7-B650-4451-90E8-E6742A1668D2">Clinical Pharmacology (12.1)</linkHtml>]</content>. Pregnant women who receive mercaptopurine have an increased incidence of miscarriage and stillbirth <content styleCode="italics">(see <linkHtml href="#ID_8732091c-1245-401a-a3d0-10f2b80fb1c8">Data</linkHtml>)</content>. Advise pregnant women of the potential risk to a fetus.</paragraph>
                              <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population(s) is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20241128"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_8732091c-1245-401a-a3d0-10f2b80fb1c8">
                           <id root="d0eacddc-ad11-47fc-b9e5-68a0119445fd"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Data</content>
                              <content styleCode="bold">
                                 <content styleCode="italics"/>
                              </content>
                           </title>
                           <effectiveTime value="20241128"/>
                           <component>
                              <section ID="ID_5850eb1e-3d0d-42ef-bdfb-203e2d735ea4">
                                 <id root="520c2856-fc2d-428c-af30-8b6d7d7c3442"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>Human Data </title>
                                 <text>
                                    <paragraph>Women receiving mercaptopurine in the first trimester of pregnancy have an increased incidence of miscarriage; the risk of malformation in offspring surviving first trimester exposure is not known. In a series of 28 women receiving mercaptopurine after the first trimester of pregnancy, 3 mothers died prior to delivery, 1 delivered a stillborn child, and 1 aborted; there were no cases of macroscopically abnormal fetuses. </paragraph>
                                 </text>
                                 <effectiveTime value="20210505"/>
                              </section>
                           </component>
                           <component>
                              <section ID="ID_b4632891-8922-4e91-a652-0777a977ea74">
                                 <id root="ba87c92c-111b-426d-a1b0-e467be6088a0"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>Animal Data </title>
                                 <text>
                                    <paragraph>Mercaptopurine was embryo-lethal and teratogenic in several animal species (rat, mouse, rabbit, and hamster) at doses less than the recommended human dose. </paragraph>
                                 </text>
                                 <effectiveTime value="20210505"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_C62D3003-4FC5-4056-81CB-BF17600F0F9F">
                     <id root="c4d2b8ff-9ed8-4ef0-a50e-b22cd51fcf57"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation </title>
                     <effectiveTime value="20241128"/>
                     <component>
                        <section ID="ID_2351014b-a1a6-41d7-a740-021ab5023db1">
                           <id root="800f674e-ba8c-4ef8-a113-5f30aba35160"/>
                           <code code="69759-9" codeSystem="2.16.840.1.113883.6.1" displayName="RISKS"/>
                           <title>
                              <content styleCode="underline">Risk Summary</content>
                              <content styleCode="bold">
                                 <content styleCode="italics"/>
                              </content>
                           </title>
                           <text>
                              <paragraph>There are no data on the presence of mercaptopurine or its metabolites in human milk, the effects on the breastfed child, or the effects on milk production. Because of the potential for serious adverse reactions in the breastfed child, advise women not to breastfeed during treatment with mercaptopurine tablets and for 1 week after the last dose. </paragraph>
                           </text>
                           <effectiveTime value="20241128"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_60726749-C0D9-42D8-A284-C24558949441">
                     <id root="56fd729a-fc33-4162-84eb-12c6c9fc0d1d"/>
                     <code code="77291-3" codeSystem="2.16.840.1.113883.6.1" displayName="FEMALES &amp; MALES OF REPRODUCTIVE POTENTIAL SECTION"/>
                     <title>8.3 Females and Males of Reproductive Potential </title>
                     <text>
                        <paragraph>Mercaptopurine tablets can cause fetal harm when administered to pregnant women <content styleCode="italics">[see <linkHtml href="#ID_29D21046-6E89-4235-96D8-0AFB48D9C7F6">Use in Specific Populations (8.1)</linkHtml>]</content>. </paragraph>
                     </text>
                     <effectiveTime value="20241128"/>
                     <component>
                        <section ID="ID_85b926d7-60a9-4f50-bd5f-627508206be9">
                           <id root="d9b3d5fd-fbcf-4a65-b6ec-b3360faf8c43"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Pregnancy Testing</content>
                           </title>
                           <text>
                              <paragraph>Verify the pregnancy status in females of reproductive potential prior to initiating mercaptopurine tablets <content styleCode="italics">[see <linkHtml href="#ID_29D21046-6E89-4235-96D8-0AFB48D9C7F6">Use in Specific Populations (8.1)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20241128"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_212a32a6-a4f2-4111-bf43-82968bbdcdec">
                           <id root="960bad2d-cde6-4278-b069-9195fcf28b3a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Contraception</content>
                              <content styleCode="bold">
                                 <content styleCode="italics"/>
                              </content>
                           </title>
                           <effectiveTime value="20241128"/>
                           <component>
                              <section ID="ID_18ccfc58-a809-42cb-bdb9-935f819d85e0">
                                 <id root="3a7b873a-ad26-4f4c-9fa7-e9bbebab1ecd"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>Females </title>
                                 <text>
                                    <paragraph>Advise females of reproductive potential to use effective contraception during treatment with mercaptopurine tablets and for 6 months after the last dose. </paragraph>
                                 </text>
                                 <effectiveTime value="20210505"/>
                              </section>
                           </component>
                           <component>
                              <section ID="ID_f127ac35-eb4b-46b4-b71b-e59a8895f4d5">
                                 <id root="12c2ca2f-2957-440e-a69a-58ba5e767ca4"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>Males </title>
                                 <text>
                                    <paragraph>Based on genotoxicity findings, advise males with female partners of reproductive potential to use effective contraception during treatment with mercaptopurine tablets and for 3 months after the last dose <content styleCode="italics">[see <linkHtml href="#ID_C16CDD4D-E66D-4E8F-8ED4-EADDBBFEBB01">Nonclinical Toxicology (13.1)</linkHtml>]</content>.</paragraph>
                                 </text>
                                 <effectiveTime value="20220311"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_78760a4a-826b-4da8-b676-7b471b3fdb35">
                           <id root="8c0783ee-f71c-459a-8bdd-88ec994bda22"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Infertility</content>
                              <content styleCode="bold">
                                 <content styleCode="italics"/>
                              </content>
                           </title>
                           <effectiveTime value="20241128"/>
                           <component>
                              <section ID="ID_b712c196-5075-4b23-bab5-98a1c80a98a9">
                                 <id root="c75b42ca-c534-4e6a-9253-ec2a6815378e"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>Females and Males </title>
                                 <text>
                                    <paragraph>Based on findings from animal studies, mercaptopurine tablets can impair female and male fertility <content styleCode="italics">[see <linkHtml href="#ID_C16CDD4D-E66D-4E8F-8ED4-EADDBBFEBB01">Nonclinical Toxicology (13.1)</linkHtml>]</content>. The long-term effects of mercaptopurine on female and male fertility, including the reversibility have not been studied. </paragraph>
                                 </text>
                                 <effectiveTime value="20220311"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_011848B0-95B4-4091-B958-E75D14E89258">
                     <id root="91473a52-c615-4f78-b39d-523037ddeb21"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use </title>
                     <text>
                        <paragraph>Safety and effectiveness of mercaptopurine tablets have been established in pediatric patients. Use of mercaptopurine tablets in pediatrics is supported by evidence from the published literature and clinical experience. Symptomatic hypoglycemia has been reported in pediatric patients with ALL receiving mercaptopurine. Reported cases were in pediatrics less than 6 years of age or with a low body mass index. </paragraph>
                     </text>
                     <effectiveTime value="20220311"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_43FD888E-E688-4DFF-9A71-D16C721FD601">
                     <id root="dd22e7db-7196-4864-8104-6ee333c3bd19"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use </title>
                     <text>
                        <paragraph>Clinical studies of mercaptopurine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or another drug therapy.</paragraph>
                     </text>
                     <effectiveTime value="20220311"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_2baab33d-4d76-43e2-85c6-85e5ef0bfc50">
                     <id root="c8c4a4ac-b2af-4190-a3ab-a098b2f65c2c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6 Renal Impairment  </title>
                     <text>
                        <paragraph>Use the lowest recommended starting dosage for mercaptopurine tablets or increase the dosing interval to every 36-48 hours in patients with renal impairment (CLcr less than 50 mL/min). Adjust the dose to maintain absolute neutrophil count (ANC) at a desirable level and for adverse reactions <content styleCode="italics">[see <linkHtml href="#ID_685380f0-baaa-4459-b776-9e3187f924e0">Dosage and Administration (2.3)</linkHtml>]</content>. </paragraph>
                     </text>
                     <effectiveTime value="20241128"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_b4c97d6f-12ca-4cd5-b9a5-26a7c4fb9df2">
                     <id root="d4612b09-b922-40b0-a530-623bed12cbff"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.7 Hepatic Impairment  </title>
                     <text>
                        <paragraph>Use the lowest recommended starting dosage for mercaptopurine tablets in patients with hepatic impairment. Adjust the dose to maintain absolute neutrophil count (ANC) at a desirable level and for adverse reactions <content styleCode="italics">[see <linkHtml href="#ID_685380f0-baaa-4459-b776-9e3187f924e0">Dosage and Administration (2.3)</linkHtml>]</content>. </paragraph>
                     </text>
                     <effectiveTime value="20241128"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_F7F4778B-2D27-453C-A65B-D71D97EBAF06">
               <id root="91774824-420a-4684-bbda-8b5608853470"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE </title>
               <text>
                  <paragraph>Signs and symptoms of mercaptopurine overdosage may be immediate (anorexia, nausea, vomiting, and diarrhea); or delayed (myelosuppression, liver dysfunction, and gastroenteritis). Dialysis cannot be expected to clear mercaptopurine. Hemodialysis is thought to be of marginal use due to the rapid intracellular incorporation of mercaptopurine into active metabolites with long persistence. </paragraph>
                  <paragraph>Withhold mercaptopurine tablets immediately for severe or life-threatening adverse reactions occur during treatment. If a patient is seen immediately following an accidental overdosage, it may be useful to induce emesis.</paragraph>
               </text>
               <effectiveTime value="20220311"/>
            </section>
         </component>
         <component>
            <section ID="ID_92AE3A2B-9963-4560-9024-854B531EE501">
               <id root="f3fc53b5-7bb6-4c88-a064-77a0a9916535"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION </title>
               <text>
                  <paragraph>Mercaptopurine is a nucleoside metabolic inhibitor, the chemical name is 6<content styleCode="italics">H</content>-purine-6-thione, 1,7-dihydro-,monohydrate. The molecular formula is C<sub>5</sub>H<sub>4</sub>N<sub>4</sub>Sâ¢H<sub>2</sub>O and the molecular weight is 170.20. Its structural formula is:</paragraph>
                  <renderMultiMedia ID="id224266172" referencedObject="E5BAAAC2-91DD-46B3-9640-92B73BE92BD0"/>
                  <paragraph>Mercaptopurine, USP is a yellow, crystalline powder. Mercaptopurine is practically insoluble in water and in ether. It has a pKa of 7.8, an average tapped density of 1.0 g/mL and average bulk density of 0.85 g/mL. It dissolves in solutions of alkali hydroxides.</paragraph>
                  <paragraph>Mercaptopurine tablets are available for oral use. Each scored tablet contains 50 mg mercaptopurine and the following inactive ingredients: corn starch, lactose monohydrate, magnesium stearate, pregelatinized starch (corn) and sodium lauryl sulfate.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Meets USP Dissolution Test 2.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250221"/>
               <component>
                  <observationMedia ID="E5BAAAC2-91DD-46B3-9640-92B73BE92BD0">
                     <text>Mercaptopurine Structural Formula</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_F23A5976-0BE2-410B-8C91-358578327389">
               <id root="109d7a90-ddc1-4307-bdd2-37b4e4394da5"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY </title>
               <effectiveTime value="20241128"/>
               <component>
                  <section ID="ID_E44834E7-B650-4451-90E8-E6742A1668D2">
                     <id root="b3015658-3ad5-424c-8315-f96bd5005ab8"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action </title>
                     <text>
                        <paragraph>Mercaptopurine is a purine analog that undergoes intracellular transport and activation to form metabolites including thioguanine nucleotides (TGNs). Incorporation of TGNs into DNA or RNA results in cell-cycle arrest and cell death. TGNs and other mercaptopurine metabolites are also inhibitors of de novo purine synthesis and purine nucleotide interconversions. Mercaptopurine was cytotoxic to proliferating cancer cells in vitro and had antitumor activity in mouse tumor models. It is not known which of the biochemical effects of mercaptopurine and its metabolites are directly or predominantly responsible for cell death.</paragraph>
                     </text>
                     <effectiveTime value="20241128"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_5E5BAB48-9006-48E3-ACE1-7A90D972FD0A">
                     <id root="a5edf000-6186-4b22-9c28-c944d19e37f5"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics </title>
                     <effectiveTime value="20241128"/>
                     <component>
                        <section ID="ID_fc4416be-a312-46e0-adbb-e2f9ffc1c1d3">
                           <id root="5ff66356-192a-41b8-8c1b-c2cabf7e3088"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Exposure-Response Relationships</content>
                              <content styleCode="bold">
                                 <content styleCode="italics"/>
                              </content>
                           </title>
                           <text>
                              <paragraph>Mercaptopurine exposure-response relationships and the time course of pharmacodynamics response are unknown. </paragraph>
                           </text>
                           <effectiveTime value="20241128"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_95A23542-7C96-4B16-B444-FB8557D334EC">
                     <id root="2177ad62-9630-4401-b218-4abaf79284f4"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics </title>
                     <text>
                        <paragraph>Following a single oral dose of mercaptopurine 50 mg under fasted conditions to adult healthy subjects, the mean AUC<sub>0-INF </sub>was 129 hâ¢ng/mL and C<sub>max</sub> was 69 ng/mL.</paragraph>
                     </text>
                     <effectiveTime value="20241128"/>
                     <component>
                        <section ID="ID_e0d92b82-f94e-4a69-a3f5-db7baf9a9400">
                           <id root="7b5cc27e-a560-47b1-9b92-9f836903f623"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Absorption</content>
                              <content styleCode="bold">
                                 <content styleCode="italics"/>
                              </content>
                           </title>
                           <effectiveTime value="20241128"/>
                           <component>
                              <section ID="ID_a7e3fd7e-e736-4a43-8e19-d05ef0bbf6e4">
                                 <id root="8316f9ba-029a-4c63-8258-b740a5fcbf0a"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>Food Effect </title>
                                 <text>
                                    <paragraph>Food has been shown to decrease the exposure of mercaptopurine.</paragraph>
                                 </text>
                                 <effectiveTime value="20210505"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_1262443e-dade-4549-8484-2e2f1a30b821">
                           <id root="0d5b3df8-45ed-4251-803c-9e3df149493e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Distribution</content>
                              <content styleCode="bold">
                                 <content styleCode="italics"/>
                              </content>
                           </title>
                           <text>
                              <paragraph>The volume of distribution usually exceeded that of the total body water. There is negligible entry of mercaptopurine into cerebrospinal fluid.</paragraph>
                              <paragraph>Plasma protein binding averages 19% over the concentration range 10 to 50 mcg/mL (a concentration only achieved by intravenous administration of mercaptopurine at doses exceeding 5 to 10 mg/kg). </paragraph>
                           </text>
                           <effectiveTime value="20241128"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_45b4ccbb-e34c-4106-a019-7b43984e7f7b">
                           <id root="276c4762-3733-4f0e-8faa-1cb4a8e61b03"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Elimination</content>
                              <content styleCode="bold">
                                 <content styleCode="italics"/>
                              </content>
                           </title>
                           <text>
                              <paragraph>The elimination half-life is less than 2 hours following a single oral dose.</paragraph>
                           </text>
                           <effectiveTime value="20241128"/>
                           <component>
                              <section ID="ID_859f87ef-c9c3-4505-ad2d-6a680c310f15">
                                 <id root="18f8ad2c-64de-4b15-8832-667566dd5b3e"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>Metabolism </title>
                                 <text>
                                    <paragraph>Mercaptopurine is inactivated via two major pathways. One is thiol methylation, which is catalyzed by the polymorphic enzyme thiopurine S-methyltransferase (TPMT), to form the inactive metabolite methyl-mercaptopurine. The second inactivation pathway is oxidation, which is catalyzed by xanthine oxidase. The product of oxidation is the inactive metabolite 6-thiouric acid. </paragraph>
                                 </text>
                                 <effectiveTime value="20210505"/>
                              </section>
                           </component>
                           <component>
                              <section ID="ID_ec5d163b-7bfd-498c-a615-bc7d0238301e">
                                 <id root="38f99630-c2c4-4493-a87a-8245f26448f8"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>Excretion </title>
                                 <text>
                                    <paragraph>Following the oral administration of radiolabeled mercaptopurine, 46% of the dose was recovered in the urine (as parent drug and metabolites) in the first 24 hours.</paragraph>
                                 </text>
                                 <effectiveTime value="20210505"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_531b98a2-c74a-4a80-8fde-0094c2cfef7e">
                     <id root="15102da4-f8cb-4d80-aeb5-e8d047930523"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>12.5 Pharmacogenomics  </title>
                     <text>
                        <paragraph>Several published studies indicate that patients with reduced TPMT or NUDT15 activity receiving usual doses of mercaptopurine, accumulate excessive cellular concentrations of active 6-TGNs, and are at higher risk for severe myelosuppression. In a study of 1028 children with ALL, the approximate tolerated mercaptopurine dosage for patients with TPMT and/or NUDT15 deficiency on mercaptopurine maintenance therapy (as a percentage of the planned dosage) was as follows: heterozygous for either TPMT or NUDT15, 50-90%; heterozygous for both TPMT and NUDT15, 30-50%; homozygous for either TPMT or NUDT15, 5-10%. </paragraph>
                        <paragraph>Approximately 0.3% (1:300) of patients of European or African ancestry have two loss-of-function alleles of the TPMT gene and have little or no TPMT activity (homozygous deficient or poor metabolizers), and approximately 10% of patients have one loss-of-function TPMT allele leading to intermediate TPMT activity (heterozygous deficient or intermediate metabolizers). The TPMT<sup>*</sup>2, TPMT<sup>*</sup>3A, and TPMT<sup>*</sup>3C alleles account for about 95% of individuals with reduced levels of TPMT activity. </paragraph>
                        <paragraph>NUDT15 deficiency is detected in &lt; 1% of patients of European or African ancestry. Among patients of East Asian ancestry (i.e., Chinese, Japanese, Vietnamese), 2% have two loss-of-function alleles of the NUDT15 gene, and approximately 21% have one loss-of-function allele. The p.R139C variant of NUDT15 (present on the <sup>*</sup>2 and <sup>*</sup>3 alleles) is the most commonly observed, but other less common loss-of-function NUDT15 alleles have been observed. </paragraph>
                        <paragraph>Consider all clinical information when interpreting results from phenotypic testing used to determine the level of thiopurine nucleotides or TPMT activity in erythrocytes, since some coadministered drugs can influence measurement of TPMT activity in blood and blood from recent transfusions will misrepresent a patientâs actual TPMT activity <content styleCode="italics">[see <linkHtml href="#ID_0e3b37a1-bd9b-4476-9745-464f5b13b677">Dosage and Administration (2.2)</linkHtml>, <linkHtml href="#ID_5b7ca743-e272-49eb-b06f-d8aa29349acc">Warnings and Precautions (5.1)</linkHtml>]</content>. </paragraph>
                     </text>
                     <effectiveTime value="20241128"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_CFCF35AD-BF92-4505-9A3E-D0ABD11A6C1A">
               <id root="6976855a-1f6e-4bda-abf6-a4c07a2e2ee4"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY </title>
               <effectiveTime value="20220311"/>
               <component>
                  <section ID="ID_C16CDD4D-E66D-4E8F-8ED4-EADDBBFEBB01">
                     <id root="3acf8b28-5c7b-42ec-9d9b-114480c1dd2b"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility </title>
                     <text>
                        <paragraph>Mercaptopurine is carcinogenic in animals. </paragraph>
                        <paragraph>Mercaptopurine causes chromosomal aberrations in cells derived from animals and humans and induces dominant-lethal mutations in the germ cells of male mice. </paragraph>
                        <paragraph>Mercaptopurine can impair fertility. In mice, surviving female offspring of mothers who received chronic low doses of mercaptopurine during pregnancy were found sterile, or if they became pregnant, had smaller litters and more dead fetuses as compared to control animals.</paragraph>
                     </text>
                     <effectiveTime value="20220311"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_D69CB87C-FBDD-439B-96BA-BBAB56C4543F">
               <id root="d7f89c50-e881-4e35-8e39-a8b5e7bb0b60"/>
               <code code="34093-5" codeSystem="2.16.840.1.113883.6.1" displayName="REFERENCES SECTION"/>
               <title>15 REFERENCES </title>
               <text>
                  <list listType="ordered">
                     <item>
                        <caption>1.</caption>OSHA Hazardous Drugs. OSHA. http://www.osha.gov/SLTC/hazardousdrugs/index.html</item>
                  </list>
               </text>
               <effectiveTime value="20220311"/>
            </section>
         </component>
         <component>
            <section ID="ID_10B53EF9-A9DB-4A9F-ABAC-2D5D0E8F167F">
               <id root="bc5a404c-74b8-42f5-a9b0-f99bd2c7d64e"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING </title>
               <text>
                  <paragraph>Mercaptopurine Tablets, USP are available containing 50 mg of mercaptopurine, USP.</paragraph>
                  <paragraph>The 50 mg tablets are off-white to light yellow, round, scored tablets debossed with <content styleCode="bold">M</content> above the score and <content styleCode="bold">547</content> below the score on one side of the tablet and blank on the other side. They are available as follows:</paragraph>
                  <paragraph>NDC 0378-3547-52<br/>bottles of 25 tablets</paragraph>
                  <paragraph>NDC 0378-3547-25<br/>bottles of 250 tablets</paragraph>
                  <paragraph>
                     <content styleCode="bold">Store at 20Â° to 25Â°C (68Â° to 77Â°F). [See USP Controlled Room Temperature.]</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Protect from moisture.</content>
                  </paragraph>
                  <paragraph>Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.</paragraph>
                  <paragraph>Mercaptopurine tablets are a cytotoxic drug. Follow special handling and disposal procedures.</paragraph>
               </text>
               <effectiveTime value="20250221"/>
            </section>
         </component>
         <component>
            <section ID="ID_3A047068-D7B3-4E45-8A50-7DDDA67ABD9E">
               <id root="6a7c1b82-65cd-48de-b154-41e10e377ba0"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION </title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Major Adverse Reactions</content>
                  </paragraph>
                  <paragraph>Advise patients and caregivers that mercaptopurine tablets can cause myelosuppression, hepatotoxicity, and gastrointestinal toxicity. Advise patients to contact their healthcare provider if they experience fever, sore throat, jaundice, nausea, vomiting, signs of local infection, bleeding from any site, or symptoms suggestive of anemia <content styleCode="italics">[see <linkHtml href="#ID_5b7ca743-e272-49eb-b06f-d8aa29349acc">Warnings and Precautions (5.1</linkHtml>, <linkHtml href="#ID_bfef2dcf-ce51-481d-9c8e-ed6f0da20250">5.2</linkHtml>, <linkHtml href="#ID_ebb44fcf-c297-4999-85cb-09f0b5a6528a">5.3)</linkHtml>]</content>. </paragraph>
                  <paragraph>
                     <content styleCode="underline">Embryo-Fetal Toxicity</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>â¢</caption>Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to inform their healthcare provider of a known or suspected pregnancy <content styleCode="italics">[see <linkHtml href="#ID_bfef2dcf-ce51-481d-9c8e-ed6f0da20250">Warnings and Precautions (5.2</linkHtml>, <linkHtml href="#ID_bd8104ed-c6a2-41ae-bf66-8f98042f266b">5.6)</linkHtml>, <linkHtml href="#ID_29D21046-6E89-4235-96D8-0AFB48D9C7F6">Use in Specific Populations (8.1)</linkHtml>]</content>. </item>
                     <item>
                        <caption>â¢</caption>Advise females of reproductive potential to use effective contraception during treatment with mercaptopurine tablets and for 6 months after the last dose <content styleCode="italics">[see <linkHtml href="#ID_60726749-C0D9-42D8-A284-C24558949441">Use in Specific Populations (8.3)</linkHtml>]</content>. </item>
                     <item>
                        <caption>â¢</caption>Advise males with female partners of reproductive potential to use effective contraception during treatment with mercaptopurine tablets and for 3 months after the last dose <content styleCode="italics">[see <linkHtml href="#ID_60726749-C0D9-42D8-A284-C24558949441">Use in Specific Populations (8.3)</linkHtml>, <linkHtml href="#ID_C16CDD4D-E66D-4E8F-8ED4-EADDBBFEBB01">Nonclinical Toxicology (13.1)</linkHtml>]</content>. </item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Lactation</content>
                  </paragraph>
                  <paragraph>Advise women not to breastfeed during treatment with mercaptopurine tablets and for 1 week after the last dose <content styleCode="italics">[see <linkHtml href="#ID_C62D3003-4FC5-4056-81CB-BF17600F0F9F">Use in Specific Populations (8.2)</linkHtml>]</content>. </paragraph>
                  <paragraph>
                     <content styleCode="underline">Infertility</content>
                  </paragraph>
                  <paragraph>Advise males and females of reproductive potential that mercaptopurine tablets can impair fertility <content styleCode="italics">[see <linkHtml href="#ID_60726749-C0D9-42D8-A284-C24558949441">Use in Specific Populations (8.3)</linkHtml>]</content>. </paragraph>
                  <paragraph>
                     <content styleCode="underline">Other Adverse Reactions</content>
                  </paragraph>
                  <paragraph>Instruct patients to minimize sun exposure due to risk of photosensitivity <content styleCode="italics">[see <linkHtml href="#ID_00f84b8b-1f8f-4650-9099-8e1c121f67d3">Adverse Reactions (6.1)</linkHtml>]</content>.</paragraph>
                  <paragraph>Manufactured for:<br/>
                     <content styleCode="bold">Mylan Pharmaceuticals Inc.</content>
                     <br/>Morgantown, WV 26505 U.S.A.</paragraph>
                  <paragraph>Revised: 2/2025</paragraph>
                  <paragraph>MCPT:RX2</paragraph>
               </text>
               <effectiveTime value="20250221"/>
            </section>
         </component>
         <component>
            <section ID="ID_2F566C1E-4C4B-4C50-8858-2A7AC1C57013">
               <id root="042703d4-889b-45f1-87f5-9815cd4d270f"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">NDC 0378-3547-52</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Mercaptopurine<br/>Tablets, USP</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">50 mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Cytotoxic Agent</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx onlyÂ Â Â Â 25 Tablets</content>
                  </paragraph>
                  <paragraph>Each tablet contains:<br/>Mercaptopurine, USPÂ Â Â Â 50 mg</paragraph>
                  <paragraph>
                     <content styleCode="bold">Usual Dosage:</content> See accompanying<br/>prescribing information.</paragraph>
                  <paragraph>Dispense in a tight, light-resistant<br/>container as defined in the USP using<br/>a child-resistant closure.</paragraph>
                  <paragraph>Keep container tightly closed.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Keep this and all medication out of<br/>the reach of children.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Store at 20Â° to 25Â°C (68Â° to 77Â°F ).<br/>[See USP Controlled Room Temperature.]</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Protect from moisture.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">WARNING:</content> This drug is <content styleCode="bold">only</content> to be taken<br/>under close medical supervision.</paragraph>
                  <paragraph>Do not take in larger doses or more frequently<br/>or for a longer time than specifically directed<br/>by the physician. Periodic blood counts are<br/>necessary to determine proper dose and to<br/>avoid ill effects.</paragraph>
                  <paragraph>Manufactured for:<br/>
                     <content styleCode="bold">Mylan Pharmaceuticals Inc.</content>
                     <br/>Morgantown, WV 26505 U.S.A.</paragraph>
                  <paragraph>Made in Puerto Rico</paragraph>
                  <paragraph>
                     <content styleCode="bold">RM3547BA6</content>
                  </paragraph>
                  <renderMultiMedia ID="id-1423480807" referencedObject="A65EFB72-54FD-4FFB-A773-D23E20E9C71E"/>
               </text>
               <effectiveTime value="20241128"/>
               <component>
                  <observationMedia ID="A65EFB72-54FD-4FFB-A773-D23E20E9C71E">
                     <text>Mercaptopurine Tablets, USP 50 mg Bottle Label </text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>